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Objective: Apoptosis of natural killer (NK) cells is increased in patients with coronary artery disease
(CAD) and may explain why NK cell levels are altered in these patients. Soluble forms of Fas and Fas
ligand (L) are considered as markers of apoptosis. Here, we investigated whether plasma levels of Fas and
FasL were associated with NK cell apoptosis and NK cell levels in CAD patients.
Methods: Fas and FasL in plasma were determined by ELISA in 2 cohorts of CAD patients; one longitu-
dinal study measuring circulating NK cells and apoptotic NK cells by ﬂow cytometry 1 day, 3 months and
12 months after a coronary event and one cross-sectional study measuring NK cell apoptosis ex vivo.
Both studies included matched healthy controls. Fas and FasL were also determined in supernatants from
NK cells undergoing cytokine-induced apoptosis in cell culture.
Results: In the 12-month longitudinal study, plasma FasL increased by 15% (p < 0.001) and NK cell levels
by 31% (p < 0.05) while plasma Fas did not change. Plasma FasL and NK cell levels were signiﬁcantly
related at 3 months and 12 months, r ¼ 0.40, p < 0.01. Furthermore, plasma FasL, but not plasma Fas,
correlated with NK cell apoptosis ex vivo in CAD patients, r ¼ 0.54, p < 0.05. In vitro, cytokine-induced
apoptosis of NK cells resulted in abundant release of FasL.
Conclusion: In CAD patients, FasL in plasma is associated with both apoptotic susceptibility of NK cells
and dynamic changes in circulating NK cells. NK cells are also themselves a potential source of soluble
FasL. Our ﬁndings link NK cell status to a soluble marker with possible atheroprotective effects thereby
supporting a beneﬁcial role of NK cells in CAD.
 2014 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Inﬂammation is considered an important component in the
atherosclerotic process. It is present not only in the vessel wall but
also in the circulation. Patients with coronary artery disease (CAD)
show systemic signs of chronic low-grade inﬂammation but
moreover, they exhibit a perturbed immune homeostasis involvingfax: þ46 (0)13 149 106.
.
r Ireland Ltd. Open access under CC Bcirculating leukocytes [1,2]. It has been shown by several,
including our own group, that the circulating levels of natural
killer (NK) cells as well as the NK cell activity are reduced in CAD
patients compared with healthy subjects, the reduction being
more pronounced in patients with unstable conditions [3e6].
However, this is necessarily not a permanent feature. NK cells
show a biological variation over time [7] and in a recently pub-
lished 12-month follow-up study of patients with a coronary
event, we demonstrated that NK cell levels could be restored to
levels similar to controls [8].
The mechanism behind the deﬁcit of NK cells in CAD is mainly
unknown but an increased apoptosis of NK cells in CAD patients has
been reported [5,9]. Activation-induced lymphocyte apoptosis isY-NC-ND license.
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bound receptors. One major pathway involves the death receptor
Fas which induces apoptosis after interacting with the Fas ligand
(FasL). Soluble forms of Fas (sFas) and FasL (sFasL) are detected in
plasma and frequently used as markers of apoptosis. In neoplastic
and autoimmune diseases, the levels of sFas and sFasL have been
positively related to circulating levels of apoptotic NK cells and T
cells [10e12]. Interestingly, sFasL levels have also been positively
associated with NK cell levels in NK cell proliferative disorders
[13,14]. In regard to cardiovascular disease, high levels of sFas in
plasma seem to indicate an increased risk [15e17] while elevations
in sFasL rather represent a proﬁle of low cardiovascular risk
[15,18,19]. The relationship between sFas or sFasL and lymphocyte
apoptosis or lymphocyte levels in CAD is unknown.
Here, our aim was to investigate whether sFas and sFasL were
positively related to NK cell apoptosis and NK cell levels in pa-
tients with acute and stable conditions of CAD, hypothesizing
that these apoptotic markers could reﬂect the NK cell status in
disease.
2. Methods
2.1. Subjects
Two independent cohorts of CAD patients (Cohorts I and II) were
analyzed. In Cohort I, 31 patients with non-ST-elevation acute
coronary syndrome (NSTE-ACS) and 34 patients with stable angina
(SA) were consecutively recruited from the Department of Cardi-
ology, University Hospital, Linköping, Sweden. NSTE-ACS patients
were included if they had a diagnosis of non-ST elevation
myocardial infarction, with the diagnosis based on typical ECG
changes (ST-T segment depression and/or T-wave inversion) and
elevated troponins. SA patients were included if they were referred
for elective coronary angiography due to effort angina class II or III
in accordance with Canadian Cardiovascular Society Classiﬁcation
and objective signs of ischemia obtained by exercise testing or
myocardial perfusion imaging. Blood samples at day 1 were
collected immediately before coronary angiography and in NSTE-
ACS patients within 24 h from admission. Longitudinal measures
were available in 15 NSTE-ACS patients and 28 SA patients, blood
samples being collected at 3 and 12 months.
In Cohort II, 16 CAD patients who had suffered a coronary event
(NSTE-ACS and/or coronary revascularization procedure) 3e6
months earlier were consecutively recruited from the same cardi-
ology department as Cohort I. Patients in Cohort II were recruited
before the inclusion in Cohort I started and none of the patients
were included in both cohorts.
Patients were not eligible in any of the cohorts if they had severe
heart failure, immunologic disorders, neoplastic disease, evidence
of acute or recent (<2 months) infection, recent major trauma,
surgery or revascularization procedure, treatment with immuno-
suppressive or anti-inﬂammatory agents (except low-dose aspirin).
In parallel with the recruitment of Cohort I and II, age and
gender matched control subjects from the region were randomly
invited from the Swedish Population Register. None of the controls
participated in both studies. Subjects who accepted the invitation
were included as controls if they were anamnestically healthy and
received no medication. Anamnesis was gained by one dedicated
nurse coordinator who also performed the blood sampling at the
University Hospital’s Outpatient Cardiology Clinic.
The studies were conducted in accordance with the ethical
guidelines of Declaration of Helsinki, and the research protocols
were approved by the Ethical Review Board of Linköping University.
Written informed consent was obtained from all patients and
controls before blood collection.2.2. Whole blood ﬂow cytometric analysis of NK cells and T cells
and their levels of apoptosis
In Cohort I, circulating levels of NK cells and T cells as well as
apoptotic NK cells and T cells were assessed by whole blood ﬂow
cytometry within 1 h from blood sampling. Cells were identiﬁed by
using the following monoclonal antibodies: anti-CD3-ﬂuorescein
isothiocyanate (FITC) and anti-CD56-allophycocyanin (APC), both
purchased from BD Biosciences (San José, CA, USA). As previously
described [6,8], whole blood and antibodies were incubated for
15 min at room temperature, erythrocytes were thereafter lysed
with FACS Lysing Solution (BD Biosciences) for 15 min at room
temperature. For the detection of apoptosis/necrosis, cells were
resuspended in 100 ml of annexin V binding buffer and incubated
with 3.5 ml of phycoerythrin (PE)-conjugated annexin V and 3.5 ml
of peridinin chlorophyll protein (PerCP)-conjugated 7-
aminoactinomyosin D (7-AAD) at room temperature for 15 min in
the dark (all reagents from BD Biosciences). Next, an aliquot of
400 ml annexin V binding buffer was added and ﬂow cytometry
analysis was performed immediately. Samples were analyzed on a
FACSCanto A or FACSCanto II (BD Biosciences). Analysis of samples
was stopped when 10 000 cells were collected in the lymphocyte
gate. Data were analyzed and subpopulations gated with
FACSDiva 6.1.2 software (BD Biosciences). Control of the instru-
ment settings was done daily with 7-color Setup Beads with
FACSDiva software or Cytometer Setup and Tracking beads (BD
Biosciences) with Cytometer Setup and Tracking software ac-
cording to the standard procedure. The ﬂow cytometry laboratory
gained accreditation status in 1996 according to ISO/IEC 17025
standards and is participating in external quality programs for
immune phenotyping (UK Neqas and Equalis). The methodological
and biological variation of lymphocyte subsets in human blood has
been reported previously [7].
2.3. Preparation of NK cells and T cells
In order to perform apoptosis assays ex vivo and in vitro, pe-
ripheral blood mononuclear cells (PBMC) were isolated by density
gradient centrifugation. After centrifugation at 400  g for 30 min,
the PBMC were collected at the interface and washed twice. For the
assessment of lymphocyte apoptosis ex vivo, NK cell and T cell
fractions were derived from patients and controls in Cohort II by
using NK Cell Negative Isolation Kit (Dynal Biotech ASA, Oslo,
Norway) as previously described [9]. For the assessment of
cytokine-induced apoptosis in vitro, NK cell and T cell fractions
were derived from blood donors by using stepwise isolation of
CD3þ and CD3 cells and subsequent positive selection of CD3-
CD56þ cells using MACS beads following the manufacturer’s pro-
tocol (Milteney Biotec, Bergich Gladbach, Germany). All selected
cell fractions were analyzed by ﬂow cytometry using anti-CD3-
APC-H7 and anti-CD56-APC (BD Biosciences). Only preparations
with >97% CD3-CD56þ cells (NK cells) or >97% CD3þ cells (T cells)
were used for further experiments.
2.4. Spontaneous NK cells and T cell apoptosis ex vivo
In Cohort II, the susceptibility to apoptosis of NK cells and T cells
was determined in ex vivo assays. Blinded analyseswere performed
involving one patient and one age- and gender-matched control in
each experimental set-up. Fractions of isolated NK cells or T cells
were cultured in RPMI culture medium supplemented with 10%
FBS, 2 mM L-glutamine, 100 mg/mL penicillin G and 100 mg/mL
streptomycin. The cells were cultured at 95% air and 5% CO2 in a
humidiﬁed atmosphere at 37 C for 18 h. Thereafter, cells were
collected, washed once and stained for 10 min on ice with annexin
Table 1
Baseline characteristics of NSTE-ACS patients and SA patients in Cohort I (day 1 prior
to coronary angiography) and clinically healthy controls.
NSTE-ACS
(n ¼ 31)
SA (n ¼ 34) Controls
(n ¼ 37)
pa
Age, years 69 (50e83) 63 (44e77) 63 (45e77) 0.155
Female, n (%) 8 (26) 6 (18) 9 (24) 0.697
Smokers, n (%) 7 (23)*** 5 (15)*** 1 (3) <0.001
Waist
circumference
(cm)
98 (93e108)* 102 (94e108)** 94 (89e99) 0.011
Hypertension, n (%) 12 (39)*** 24 (71)*** 0 <0.001
Diabetes, n (%) 3 (10) 4 (12) 0 0.111
Statin treatment,
n (%)
9 (29)*** 28 (82)*** 0 <0.001
Total cholesterol,
mmol/l
5.3 (4.4e6.4) 5.0 (4.1e5.5) 5.5 (4.9e6.4) 0.157
LDL cholesterol,
mmol/l
3.3 (1.9e4.1) 2.7 (2.2e3.5)** 3.4 (2.8e4.0) 0.030
HDL cholesterol,
mmol/l
1.3 (1.0e1.5) 1.2 (1.1e1.4)* 1.4 (1.2e1.8) 0.064
Triglycerides,
mmol/l
1.4 (1.2e1.8)* 1.4 (1.1e1.9)* 1.1 (0.9e1.6) 0.026
Cystatin C, mg/l 1.1 (1.0e1.3) 1.1 (1.0e1.2) 1.1 (1.1e1.2) 0.659
IL-6, pg/ml 4.3 (2.2e7.7)*** 3.2 (2.0e6.5)*** 1.4 (1.0e2.2) <0.001
NSTE-ACS, non-ST-elevation acute coronary syndrome; SA, stable angina. Ordinal
data are presented as median (inter-quartile range).
* p< 0.05 compared with controls, ** p< 0.01 compared with controls, *** p< 0.001
compared with controls.
p values < 0.05 are indicated in bold.
a ManneWhitney U-test was used for comparison between two groups. Kruskale
Wallis one-way analysis of variance was used for comparison between 3 groups.
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nheim, Germany). Finally, samples were analyzed on Bectone
Dickinson LSR II Flow Cytometer using CellQuest software (10 000
cells were analyzed in each sample). The number of apoptotic cells
were also measured directly after isolation and used as a baseline
reference. Quality assurance procedures using standard operating
practice and Spherotech 8-peak validation beads (Becton Dick-
inson) every second week ensured reproducibility.
2.5. Cytokine-induced apoptosis of NK cells and T cells in vitro
The ability of NK cells and T cells to secrete Fas or FasL upon
cytokine-induced apoptosis was determined in vitro. NK cell and T
cell fractions were isolated from 5 healthy blood donors (according
to the procedure described above), plated at 100 000 cells per well
in 96-well plates and cultured at 37. NK cells or T cells were either
left unstimulated, stimulated with interleukin (IL)-15 alone (15 ng/
ml, R&D Systems, UK) or with IL-15 and IL-12 p70 (3 ng/ml, R&D
Systems, UK) according to a protocol by Ross and Caligiuri [20]. After
48 h of stimulation, supernatants were collected. Apoptosis was
determined by ﬂow cytometry after staining with APC-conjugated
annexin V and antibodies against CD3 (APC/H7) and CD56 (FITC).
2.6. Measurements of Fas, FasL and interleukin-6 in plasma and
after stimulation in vitro
Concentrations of Fas and FasL were determined in plasma
samples from Cohort I and II and in cell supernatants after in vitro
release by using Quantikine ELISA kit (R&D systems, Abingdon,
UK) following the manufacturer’s instructions. Quantiﬁcations of
IL-6 were done in plasma samples from Cohort I by using
QuantiGlo Chemiluminescent ELISA (R&D systems) following the
manufacturer’s instructions and the plates were read in a lumin-
ometer (Biotek, Germany). The limits of detection were as follows;
Fas and FasL both 7.8 pg/ml and IL-6 0.48 pg/ml. Interassay co-
efﬁcients or variation were <3%, <10% and <5% for Fas, FasL and IL-
6, respectively. Samples were analyzed in duplicate with an intra-
assay coefﬁcient of variance for Fas, FasL and IL-6 of 7.5%,<8.0% and
<15%, respectively.
2.7. Statistical analyses
IBM SPSS Statistics 19 (SPSS Inc., Chicago, IL, USA) was used for
all statistical analyses.
The Pearson’s chi-square test and ManneWhitney U-test were
used for analyses between two groups and KruskaleWallis one-way
analysis of variance for comparison between 3 groups. The differ-
ences between related samples were analyzed by Friedman’s test.
Bivariate correlations were analyzed by Spearman’s rank correlationTable 2
Soluble markers of apoptosis, proportions of NK cells and Tcells (% of lymphocytes) and pr
SA patients in Cohort I (day 1 prior to coronary angiography) and clinically healthy cont
NSTE-ACS (n ¼ 31) SA (
sFas, pg/ml 7308 (6235e8364) 7010
sFasL, pg/ml 49 (35e52)*,*** 54
NK cells, % 12 (9.8e15)* 12
T cells, % 76 (68e80)** 75
Apoptotic NK cells, % 0.4 (0.2e0.8) 1.0
Apoptotic T cells, % 0.5 (0.3e1.1) 1.3
Soluble, s; NSTE-ACS, non-ST-elevation acute coronary syndrome; SA, stable angina; Fas
quartile range).
* p < 0.05 compared with controls, ** p < 0.01 compared with controls, *** p < 0.05 com
p values < 0.05 are indicated in bold.
a ManneWhitney U-test was used for comparison between two groups. KruskaleWalcoefﬁcient. Statistical signiﬁcances were set at a two-tailed p-value
of <0.05. Values are given as median (inter-quartile range).
3. Results
3.1. Plasma levels of sFasL are associated with recovery of NK cell
levels in CAD patients (Cohort I)
Clinical and laboratory characteristics of Cohort I with age and
gender matched controls are summarized in Table 1. Compared
with controls, the prevalence of smoking was higher in NSTE-ACS
and SA patients. Also, the waist circumference was larger in both
patient groups. None of the controls were treated with antihyper-
tensive drugs or statin. In the SA group, LDL cholesterol levels were
lower than in NSTE-ACS and controls while triglyceride levels were
higher in both patient groups. Also, IL-6 levels were higher in NSTE-
ACS and SA patients than in controls, 4.3 (2.2e7.7), 3.2 (2.0e6.5)
and 1.4 (1.0e2.2) pg/ml, respectively, p < 0.001. The levels of sFas,
sFasL and subsets of NK and Tcells are presented in Table 2. At day 1,
the levels of sFas were similar across groups while sFasL levels wereoportions of early apoptotic NK and Tcell subsets (% of NK or T cells) in NSTE-ACS and
rols.
n ¼ 34) Controls (n ¼ 37) pa
(6347e8134) 7546 (6414e8611) 0.785
(39e64) 52 (43e74) 0.049
(9.1e18)* 18 (11e28) 0.020
(70e80)** 65 (60e74) 0.001
(0.4e1.8) 0.6 (0.4e2.1) 0.906
(0.6e1.8) 0.7 (0.4e2.2) 0.372
L, Fas ligand; NK cell, natural killer cell. Ordinal data are presented as median (inter-
pared with SA patients.
lis one-way analysis of variance was used for comparison between 3 groups.
Fig. 1. The correlation between sFasL levels and proportions of NK cells (% of all
lymphocytes) in CAD patients 3 months after a coronary event (Cohort I), r ¼ 0.40,
p < 0.01.
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trols. In the total lymphocyte population, the proportions of NK
cells were lower in both NSTE-ACS and SA patients compared with
controls. In the NK cell population, the proportions of early
apoptotic (annexin Vþ/7-AAD-) cells were low in all groups
(Table 2). Late-stage apoptotic or already dead lymphocyte subsets
(annexin Vþ/7-AADþ) were not detectable in any blood samples.
In total, 43 patients in Cohort I (15 NSTE-ACS and 28 SA)
participated in the longitudinal study. Among them, 33 (77%) had
undergone coronary revascularization while 10 (23%) had obtained
optimized anti-anginal drug therapy. During follow-up, all patients
received treatment with statin. The longitudinal changes of sFas,
sFasL, IL-6 and subsets of NK and T cells are shown in Table 3. Over
12 months, the levels of sFasL showed a relative increase by 17
(2.0e39) % in the NSTE-ACS group and 15 (0.0e30) % in the SA
group, p for both <0.01. In all 43 patients, the relative increase in
sFasL during 12-month follow-up was 15 (0.0e32) %, p < 0.001.
Over the same period, the relative increase in NK cells was 35
((1.5)e57) % in the NSTE-ACS group and 24 ((6.8)e75) % in the
SA group, p < 0.01 and <0.05, respectively. In all 43 patients, the
increase in NK cells during 12-month follow-upwas 31 ((4.0)e57)
%, p < 0.05. At day 1, there were no correlations between sFas or
sFasL on one hand, and NK cells or apoptotic NK cells on the other
hand, neither in patients nor in control subjects. Instead, positive
correlationswere seen between sFasL and proportions of NK cells in
patients during follow-up, both at 3 months (r ¼ 0.40, p < 0.01, see
Fig. 1) and 12months (r¼ 0.43, p< 0.01). Weaker correlations were
also seen between sFasL and absolute numbers of NK cells at 3
months (r ¼ 0.28, p < 0.05) and 12 months (r ¼ 0.31, p ¼ 0.06) and
between relative increase in NK cells and relative increase in sFasL
at 3 months (r ¼ 0.31, p < 0.05). In bivariate correlation analyses,
using signiﬁcance level of <0.01, the proportions of NK cells or
plasma levels of FasL were not correlated with age, gender, smok-
ing, or waist circumference. Neither were NK cell levels or plasma
sFasL correlated with plasma levels of total cholesterol, LDL
cholesterol, HDL cholesterol, triglycerides, cystatin C, IL-6 or sFas at
any time point.3.2. Plasma levels of sFasL are associated with increased
susceptibility to NK cell apoptosis in CAD patients (Cohort II)
All patients in Cohort II were recruited 3e6 months after a
coronary event thus being in a similar clinical stage as Cohort I
during follow-up. In pairwise experiments, spontaneous apoptosis
of freshly isolated NK cells and T cells was compared in 16 patients
and 16 age and gender matched healthy controls. Besides a brief
summary of participants’ clinical characteristics, Table 4 shows the
plasma levels of sFas and sFasL and the apoptotic susceptibility of
NK cells and T cells. The levels of sFas or sFasL did not differTable 3
Plasma levels of sFas, sFasL and IL-6, proportions of NK and T cells (% of lymphocytes) and
analysis of CAD patients with a coronary event; day 1 (prior to coronary angiography), 3
Day 1 3 Mo
sFas, pg/ml 7275 (6332e8279) 7849
sFasL, pg/ml 51 (37e60) 55
IL-6, pg/ml 3.8 (2.1e6.5) 2.2
NK cells, % 12 (8.6e16) 14
NK cells/ml 250 (142e371) 291
T cells, % 76 (69e80) 75
T cells/ml 1700 (990e2128) 1415
Apoptotic NK cells, % 0.5 (0.2e1.3) 1.1
Apoptotic T cells, % 1.0 (0.5e1.6) 1.4
Soluble, s; Fas L, Fas ligand; interleukin-6, IL-6; NK cell, natural killer cell. Ordinal data a
a The differences over time were analyzed by Friedman’s test.between groups. NK cells from patients were signiﬁcantly more
susceptible to apoptosis compared with NK cells from controls. T
cells, on the other hand, were less prone to apoptosis compared
with NK cells with no difference between groups. In patients, the
levels of sFasL were signiﬁcantly correlated with susceptibility to
NK cell apoptosis (r ¼ 0.54, p < 0.05, see Fig. 2), whereas no such
correlation was seen in controls (r ¼ 0.08, NS). There was no cor-
relation between sFasL and apoptosis of T cells, neither between
sFas and apoptosis of NK cells or T cells.3.3. NK cells undergoing apoptosis are a major source of FasL
To further evaluate the association between sFasL and apoptosis,
NK cells and T cells from blood donors were cultured under stim-
ulatory conditions to induce apoptosis. After 48 h stimulation with
IL-15, NK cells showed increased size, granularity and CD56
expression (as indicators of activation) but also increased apoptosis
compared with unstimulated cells (Fig. 3). Stimulation with a
combination of IL-15 and IL-12 resulted in a larger proportion of
apoptotic NK cells compared with IL-15 alone. T cells, on the other
hand, were less prone to enter apoptosis both spontaneously and in
the presence of IL-15 and/or IL-12 (data not shown). As shown in
Fig. 4, the concentrations of sFasL increased markedly in superna-
tants from NK cells stimulated with IL-15 compared with medium
alone and increased even more, up to 20-fold, when NK cells were
stimulated with IL-15 and IL-12. Compared with NK cells, T cellsproportions of early apoptotic NK cells and T cells (% of NK or T cells) in a longitudinal
months and 12 months (Cohort I, n ¼ 43, 15 NSTE-ACS, 28 SA).
nths 12 Months pa
(6451e8790) 7746 (6848e8869) 0.689
(42e63) 57 (43e70) <0.001
(1.2e3.1) 2.2 (1.3e3.1) 0.002
(9.7e20) 16 (11e20) 0.011
(200e375) 300 (237e448) <0.001
(69e80) 74 (68e78) 0.064
(995e2144) 1590 (1070e2115) 0.159
(0.5e2.2) 0.9 (0.5e1.2) 0.687
(0.6e2.5) 0.7 (0.4e1.4) 0.146
re presented as median (inter-quartile range).
Table 4
Clinical characteristics, plasma levels of sFas and sFasL and ex vivo apoptosis of NK
cells and T cells in 16 matched pairs of CAD patients 3e6 months after a coronary
event (Cohort II) and clinically healthy controls.
Patients Controls pa
n ¼ 16 n ¼ 16
Age, years 60 (58e65) 60 (55e62) 0.210
Female, n (%) 2 (14) 2 (14) 1.000
Smokers, n (%) 2 (14) 2 (14) 1.000
Body mass index, kg/m2 25 (24e30) 25 (24e38) 0.569
sFas, pg/ml 8087 (6932e8845) 7187 (6261e8035) 0.216
sFasL, pg/ml 55 (48e66) 57 (48e63) 0.926
NK cell apoptosis 2.52 (1.75e3.37) 2.00 (1.35e2.77) 0.024
T cell apoptosis 0.87 (0.79e1.05) 0.65 (0.55e0.97) 0.220
NSTE-ACS, non-ST-elevation acute coronary syndrome; SA, stable angina; soluble, s;
Fas L, Fas ligand; NK cell, natural killer cell. Ordinal data are presented as median
(inter-quartile range). Ex vivo apoptosis of NK cells and T cells is presented as fold
increase compared to baseline.
a ManneWhitney U-test was used for comparison between the groups.
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lation. The concentrations of sFas in non-stimulated supernatants
were low but NK cell release of sFas increased around 5-fold and T
cell release of sFas around 2-fold upon stimulation (data not
shown).4. Discussion
In the present study, we provide evidence for a dynamic rela-
tionship between sFasL and NK cells in CAD patients. The novel
ﬁndings can be summarized as follows: 1) plasma levels of sFasL
were associated with recovery of NK cell levels in patients after a
coronary event, 2) sFasL in plasma was associated with increased
susceptibility to NK cell apoptosis in CAD patients and 3) apoptotic
NK cells were themselves found to be a source of FasL.
The reduction of NK cells in CAD patients is well documented
[3e6] and has been attributed to increased apoptosis of these cells
[5,9]. However, the increase in circulating NK cells that occurs in
CAD patients after a coronary event [8] may also indicate an
increased proliferation of these cells. A balance between apoptotic
and proliferative rates is critical for maintaining homeostasis andFig. 2. The correlation between sFas levels and NK cell apoptosis ex vivo (shown as
fold increase compared to baseline) in CAD patients 3e6 months after a coronary event
(Cohort II), r ¼ 0.54, p < 0.05.normally, increased proliferation of cells is linked to increased
apoptosis. Although FasL is best known for its death-inducing
function and as such, is considered a marker of apoptosis, it also
has a role as signaling receptor in proliferation [21e23]. The asso-
ciation between sFasL and NK cell recovery in patients after a cor-
onary event suggests that sFasL not only reﬂects an increased
apoptotic rate but rather an increased apoptotic/proliferative rate of
NK cells. Interestingly, previous studies have shown that plasma
levels of sFasL are increased in NK cell proliferative disorders but
not in other lymphoproliferative disorders like T cell leukemia or T
and B cell lymphoma [13,14]. Furthermore, the high sFasL levels in
NK cell proliferative disorders become normalized after chemo-
therapy when NK cell levels decline [14].
In the present study, there were no correlations between sFas or
sFasL and circulating apoptotic lymphocytes in CAD patients at any
time point. Such correlations have been reported in gastric cancer
[10,11] aswell as in systemic lupus erythematosus [12]. In the studies
of gastric cancer, remarkably high proportions of apoptotic NK cells
and CD8þ Tcells in blood were reported; 20% in patients and 10% in
healthy controls [10,11]. In the study byCourtneyet al. [12], 4% of the
lymphocytes were apoptotic in patients with systemic lupus ery-
thematosus comparedwith 1% in controls. Since apoptosis is a time-
sensitive process, we always performed ﬂow cytometry within 1 h
from blood sampling. We found low proportions of apoptotic NK
cells and T cells, around 1%, in both CAD patients and controls.
However, when apoptosis was assessed ex vivo, NK cells from CAD
patientsweremore susceptible to apoptosis comparedwithNK cells
from controls. Moreover, susceptibility to NK cell apoptosis was
signiﬁcantly associated with plasma sFasL in patients, but not in
control subjects, supporting the hypothesis that sFasL is associated
with NK cell apoptosis under disease conditions.
Both NK cells and cytotoxic T cells are potential sources of sFasL
[21,22,24]. To further evaluate this, we isolated human NK cells and
T cells and compared their capacity to release FasL upon cytokine-
induced apoptosis. In the 48-h stimulation assay, the NK cell release
of FasL was particularly abundant indicating that apoptotic NK cells
themselves may be a prominent source of sFasL.
In previous studies, sFasL has emerged as a possible athero-
protective marker. Blanco-Colio et al. [19] showed a positive cor-
relation between sFasL levels and forearm reactive hyperemia in
patients with CAD speculating that normal endothelial cells
contributed to circulatory levels of sFasL. Furthermore, low levels of
sFasL have been reported in patients with manifest CAD as well as
in individuals at high cardiovascular risk [17,18]. FasL is cleaved
from the cell membrane to produce a soluble form. In contrast to
membrane-bound FasL, the soluble form has been associated with
anti-apoptotic and anti-inﬂammatory effects. In experimental set-
tings, the soluble form is 1000-fold less active than the membrane-
bound form [22] and moreover, it has been shown to antagonize
the effects of membrane-bound FasL by competitive binding to Fas
without inducing apoptosis [25]. It may be tempting to speculate
that an increase in sFasL is needed to counteract enhanced
apoptosis of NK cells in order to raise and/or maintain the levels of
NK cells. Our results indicate that NK cells themselves are a po-
tential source of sFasL in the circulation. During the cardiac reha-
bilitation phase, it is also possible that sFasL is released by
endothelial cells as an indicator of improved endothelial function
[19]. Improved endothelial function is supposed to be associated
with an improved inﬂammatory state, which in its turn may raise
NK cell levels. Based on experimental studies, an inﬂammatory
milieu has been associated with inhibited NK cell development and
shortened survival of NK cells [26].
The descriptive study design is one limitation of our study.
Another limitation is the small size of study populations. We were
thus not able to investigate the impact of possible confounders,
Fig. 3. One illustrative example of morphological and phenotypical changes of puriﬁed natural killer (NK) cells derived from blood donors. Cells were cultured for 48 h in medium
only or in the presence of interleukin (IL)-15 or IL-12 þ IL-15. Activated cells were deﬁned by increase in cell size accompanied by a modest increase in granularity compared with
resting cells. Moreover, activated cells showed a higher expression of CD56 (CD56bright cells). Apoptotic cells, on the other hand, were deﬁned by decrease in cell size and increased
granularity compared with resting cells. Apoptosis was also conﬁrmed by Annexin V staining in parallel experiments. Compared with medium alone, incubation with IL-15
increased the proportions of activated and apoptotic NK cells. It also increased the proportion of CD56bright cells. Incubation with IL-12 þ IL-15 resulted in more apoptotic NK
cells compared with IL-15 alone. The lower proportions of activated NK cells as well as CD56bright cells after incubation with IL-12 þ IL-15 was probably due to increased activation-
induced apoptosis.
A. Szymanowski et al. / Atherosclerosis 233 (2014) 616e622 621such as smoking, hypertension or diabetes, on sFas or sFasL levels.
On the other hand, the patient cohorts recruited at one single site
were well characterized and treated according to current guide-
lines. The combined use of longitudinal analyses of circulating cells
and ex vivo analyses may also be considered a strength.
To summarize, we show for the ﬁrst time that sFasL in plasma is
associated with an increased susceptibility to NK cell apoptosis inCAD patients and also, that an increase in sFasL following treatment
of a coronary event is associated with an increase in circulating NK
cells. Our ﬁndings link NK cell status to a soluble marker with
possible atheroprotective effects and may thereby support a
beneﬁcial role for NK cells in CAD. It remains to be conﬁrmed in
larger studies of CAD patients that sFasL is useful to monitor
changes in NK cell levels. Also, it needs to be evaluated in
Fig. 4. Release of Fas ligand (L) by puriﬁed subsets of natural killer (NK) cells (CD3-
56þ) and T cells (CD3þ) derived from blood donors. Fractions of 100 000 cells were
cultured in medium alone, IL-15 (15 ng/ml) or IL-15 þ IL-12 (15 and 3 ng/ml respec-
tively) for 48 h in 37 C. Thereafter supernatants were collected and analyzed for FasL,
n ¼ 5.
A. Szymanowski et al. / Atherosclerosis 233 (2014) 616e622622prospective studies whether an increase of sFasL after a coronary
event is a good prognostic sign.
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